Denise Vera Scots-Knight

Chief Executive Officer & Co-Founder at Mereo BioPharma Group Plc

Denise Vera Scots-Knight

Denise Vera Scots-Knight

Chief Executive Officer & Co-Founder at Mereo BioPharma Group Plc

Overview
Career Highlights

OncoMed Pharmaceuticals, Inc.
Phase4 Partners Ltd.
Phase4 Partners Ltd.

RelSci Relationships

882

Number of Boards

17

Birthday

1960

Age

61

Number of Awards

1

Relationships
RelSci Relationships are individuals Denise Vera Scots-Knight likely has professional access to. A relationship does not necessarily indicate a personal connection.

Director at Infant Bacterial Therapeutics AB

Relationship likelihood: Strong

Professional at Baines Peter Consulting

Relationship likelihood: Strong

CMO & Co-Founder at Mereo BioPharma Group Plc

Relationship likelihood: Strong

President at Bioleap, Inc. (Florida)

Relationship likelihood: Strong

Advisor at Phase4 Partners Ltd.

Relationship likelihood: Strong

Co-Founder at Mereo BioPharma Group Plc

Relationship likelihood: Strong

Chairman & Chief Executive Officer at Allegro Advisors Pvt Ltd.

Relationship likelihood: Strong

Director, President & Chief Executive Officer at Albireo Pharma, Inc.

Relationship likelihood: Strong

Co-Founder at Mereo BioPharma Group Plc

Relationship likelihood: Strong

President, Chief Executive Officer & Director at Nkarta, Inc.

Relationship likelihood: Strong

Paths to Denise Vera Scots-Knight
Potential Connections via
Relationship Science
You
Denise Vera Scots-Knight
Chief Executive Officer & Co-Founder at Mereo BioPharma Group Plc
Education
BSc (Honours)

Birmingham has been challenging and developing great minds for more than a century. Characterised by a tradition of innovation, research at the University has broken new ground, pushed forward the boundaries of knowledge and made an impact on people's lives. We continue this tradition today and have ambitions for a future that will embed our work and recognition of the Birmingham name on the international stage. Universities are never complete. They develop as new challenges and opportunities occur. At Birmingham we innovate, we push the frontiers of understanding; we ask new research questions, we turn theory through experiment into practice because that's what great universities do.

Diploma in Company Direction

Institute of Corporate Directors is a Canadian nonprofit company located in Toronto, ON, that promotes governance and develops leadership skills. The firm was founded by Brian J. Gibson. Rahul K. Bhardwaj is the CEO, in this role since 2016.The company says this about itself: ICD is treasury's trusted, independent portal provider of money market funds and other short-term investments. We provide intuitive technology and unbiased access to over 300 investment products through ICD Portal, a model in the industry for trading, reporting and analysis. Through our Global Trade Desk, located in London, Boston and San Francisco, we offer follow-the-sun support and expert service.

Undergraduate Degree

University of California Berkeley National rankings: In a National Research Council analysis of 212 doctoral programs at American universities, 48 Berkeley programs place among the top 10 nationwide. Faculty awards and honors: There are 8 Nobel Laureates, 32 MacArthur Fellows, and 4 Pulitzer Prize winners among the current faculty. History of UC Berkeley: Historical highlights, arranged by topic, following the campus's development — from UC's founding in 1868 to a turn-of-the-century building boom, a research explosion in the 1930s, the Free Speech Movement of the '60s, and Berkeley's key role today in science and technology revolutions. Timeline of discoveries and contributions by UC Berkeley scholars. Traditions of Cal: Who was the Angel of Death? What's with the "Big C" up there in the hills — and why is it sometimes green? Who wears Oski's jolly bear head and size 54 yellow sweater? Tours and webcams: Check out what's happening on Sproul Plaza, the campus's true heart. See stunning live views of the Bay Area from the Lawrence Hall of Science's perch in the Berkeley hills. Chancellor and administration: Information on Chancellor Robert Birgeneau, Executive Vice Chancellor and Provost George W. Breslauer, and how the university is organized. Organizational charts are included. UC System overview and links: On the campuses, laboratories, and medical centers that comprise UC's public educational system, as well as UC's K-12 partnerships, economic impact, and agriculture and environmental resources.

Career History
President
2019 - Current

OncoMed Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which focuses on discovering and developing novel therapeutics for cancer's growth, resistance, recurrence and metastasis. The company was founded by Michael F. Clarke and Max Wicha in August 2004 and is headquartered in Redwood City, CA.

Chief Executive Officer & Co-Founder
2015 - Current

Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). The company was founded by Denise Vera Scots-Knight, Charles Edward Sermon, Alastair Graham MacKinnon, and John P. Richard in March 10, 2015 and is headquartered in London, the United Kingdom.

Managing Partner
2010 - Prior

Long known as one of the leading life science venture capital firms based in Europe, Phase4 Partners, formerly known as Phase4 Ventures, has more recently expanded its mission to include a range of innovative investment vehicles to meet the needs of major pharmaceutical companies as well as sophisticated private and institutional investors from around the world. Founded in 1999 with its home office in London, Phase4 has invested over $400 million in 24 companies in both Europe and the US, including such notable successes as Pharmion, Arakis, Proteolix, Albireo, and OncoMed (NASDAQ: OMED). Phase4 is particularly proud of its key role in funding the development of breakthrough products such as Kyprolis (acquired by Onyx when it purchased Proteolix); Ultibro Breezhaler (a Novartis product originally developed by Arakis); and Vidaza and Thalomid (both acquired by Celgene when it purchased Pharmion); as well as important advances now in clinical trials including OncoMed’s line of innovative products directed at blocking cancer stem cells and Albireo’s elobixibat, now in Phase III studies being conducted by Albireo’s partner Ferring. All of these products offer significant improvements in the treatment of serious diseases while having the potential to generate large profits for the companies involved as well as our investors. Phase4 is a member of the British Private Equity and Venture Capital Association (BVCA), and the European Private Equity and Venture Capital Association (EVCA).

Transactions
Details Hidden

Mereo BioPharma Group Plc raised money in a private placement transaction

Investments
Details Hidden

Long known as one of the leading life science venture capital firms based in Europe, Phase4 Partners, formerly known as Phase4 Ventures, has more recently expanded its mission to include a range of innovative investment vehicles to meet the needs of major pharmaceutical companies as well as sophisticated private and institutional investors from around the world. Founded in 1999 with its home office in London, Phase4 has invested over $400 million in 24 companies in both Europe and the US, including such notable successes as Pharmion, Arakis, Proteolix, Albireo, and OncoMed (NASDAQ: OMED). Phase4 is particularly proud of its key role in funding the development of breakthrough products such as Kyprolis (acquired by Onyx when it purchased Proteolix); Ultibro Breezhaler (a Novartis product originally developed by Arakis); and Vidaza and Thalomid (both acquired by Celgene when it purchased Pharmion); as well as important advances now in clinical trials including OncoMed’s line of innovative products directed at blocking cancer stem cells and Albireo’s elobixibat, now in Phase III studies being conducted by Albireo’s partner Ferring. All of these products offer significant improvements in the treatment of serious diseases while having the potential to generate large profits for the companies involved as well as our investors. Phase4 is a member of the British Private Equity and Venture Capital Association (BVCA), and the European Private Equity and Venture Capital Association (EVCA).

Public Holdings
Restricted data only for RelSci Professional users.
Awards & Honors
Fulbright Scholar
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Denise Vera Scots-Knight. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Denise Vera Scots-Knight's profile does not indicate a business or promotional relationship of any kind between RelSci and Denise Vera Scots-Knight.